Ratings by Guggenheim (Delma Caiati)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/20/2026 | Rapport Therapeutics | RAPP | Maintain | Buy (N/A) |
|
Details | ||
| 10/12/2026 | LB Pharmaceuticals Inc | LBRX | Maintain | Buy (Buy) |
|
Details | ||
| 10/5/2026 | Neurocrine Bio. | NBIX | New Coverage | Buy (N/A) |
143.18 (142.70) |
-0.34% | Details | |
| 10/5/2026 | Xenon Pharmaceuticals | XENE | New Coverage | Buy (N/A) |
38.02 (35.34) |
-7.05% | Details | |
| 10/5/2026 | Ovid Therapeutics Inc | OVID | New Coverage | Buy (N/A) |
2.38 (2.16) |
-9.24% | Details | |
| 10/5/2026 | LB Pharmaceuticals Inc | LBRX | New Coverage | Buy (N/A) |
36.99 (38.73) |
4.7% | Details | |
| 10/5/2026 | MapLight Therapeutics | MPLT | New Coverage | Neutral (N/A) |
9.82 (7.97) |
-18.84% | Details | |
| 10/5/2026 | Rapport Therapeutics | RAPP | New Coverage | Buy (N/A) |
32.17 (25.93) |
-19.4% | Details |
